Sasse, S., Klimm, B., Goergen, H., Fuchs, M., Heyden-Honerkamp, A., Lohri, A., Koch, O., Wilhelm, M., Trenn, G., Finke, J., Mueller, R. P., Diehl, V., Eich, H. T., Borchmann, P. and Engert, A. (2012). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann. Oncol., 23 (11). S. 2953 - 2960. OXFORD: OXFORD UNIV PRESS. ISSN 0923-7534

Full text not available from this repository.

Abstract

To evaluate long-term toxicity and efficacy of a combined modality strategy including extended-field radiotherapy (EF-RT) or involved-field radiotherapy (IF-RT), the German Hodgkin Study Group carried out a follow-up analysis in patients with early unfavorable Hodgkin's lymphoma (HL). One thousand two hundred and four patients were randomized to four cycles of chemotherapy followed by either 30 Gy EF- or 30 Gy IF-RT (HD8 trial); 532 patients in each treatment arm were eligible. At 10 years, no arm differences were revealed with respect to freedom from treatment failure (FFTF) (79.8% versus 79.7%), progression-free survival (79.8% versus 80.0%), and overall survival (86.4% versus 87.3%). Non-inferiority of IF-RT was demonstrated for the primary end point FFTF (95% confidence interval for hazard ratio 0.72-1.25). Elderly patients had a poorer outcome when treated with EF-RT. So far, 15.0% of patients in arm A and 12.2% in arm B died, mostly due to secondary malignancies (5.3% versus 3.4%) or HL (3.2% versus 3.4%). After EF-RT, there were more secondary malignancies overall (58 versus 45), especially acute myeloid leukemias (11 versus 4). Radiotherapy intensity reduction to IF-RT does not result in poorer long-term outcome but is associated with less acute toxicity and might be associated with less secondary malignancies.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Sasse, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klimm, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goergen, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuchs, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heyden-Honerkamp, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lohri, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Koch, O.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wilhelm, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Trenn, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Finke, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller, R. P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Diehl, V.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eich, H. T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engert, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-479977
DOI: 10.1093/annonc/mds110
Journal or Publication Title: Ann. Oncol.
Volume: 23
Number: 11
Page Range: S. 2953 - 2960
Date: 2012
Publisher: OXFORD UNIV PRESS
Place of Publication: OXFORD
ISSN: 0923-7534
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
BREAST-CANCER RISK; 2ND MALIGNANCY; DISEASE; CHEMOTHERAPY; RADIATION; TRIAL; THERAPY; SURVIVORS; SUPERIOR; LEUKEMIAMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/47997

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item